Publication:
Combination Therapy With Semaglutide and Dapagliflozin as an Effective Approach for the Management of Type A Insulin Resistance Syndrome: A Case Report.

Simple item page
dc.contributor.authorMartinez-Montoro, Jose Ignacio
dc.contributor.authorPinzon-Martín, Jose Luis
dc.contributor.authorDamas-Fuentes, Miguel
dc.contributor.authorFernandez-Valero, Andrea
dc.contributor.authorTinahones, Francisco J
dc.contributor.funderInstituto de Salud Carlos III
dc.contributor.funderEuropean Regional Development Fund
dc.date.accessioned2023-05-03T13:39:53Z
dc.date.available2023-05-03T13:39:53Z
dc.date.issued2022-03-07
dc.description.abstractType A insulin resistance (IR) syndrome is a very uncommon genetic disorder affecting the insulin receptor (INSR) gene, characterized by severe IR without the presence of obesity. Patients with this condition will eventually develop diabetes, presenting a variable response to insulin-sensitizers, such as metformin and thiazolidinediones, and high doses of insulin. We report for the first time the results of the use of combination therapy with a glucagon-like peptide-1 receptor agonist and a sodium-glucose cotransporter 2 inhibitor for the treatment of diabetes in the context of type A IR syndrome.
dc.description.versionSi
dc.identifier.citationMartínez-Montoro JI, Pinzón-Martín JL, Damas-Fuentes M, Fernández-Valero A, Tinahones FJ. Combination Therapy With Semaglutide and Dapagliflozin as an Effective Approach for the Management of Type A Insulin Resistance Syndrome: A Case Report. Front Endocrinol (Lausanne). 2022 Apr 14;13:838887
dc.identifier.doi10.3389/fendo.2022.838887
dc.identifier.issn1664-2392
dc.identifier.pmcPMC9046779
dc.identifier.pmid35498407
dc.identifier.pubmedURLhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9046779/pdf
dc.identifier.unpaywallURLhttps://www.frontiersin.org/articles/10.3389/fendo.2022.838887/pdf
dc.identifier.urihttp://hdl.handle.net/10668/20559
dc.journal.titleFrontiers in endocrinology
dc.journal.titleabbreviationFront Endocrinol (Lausanne)
dc.language.isoen
dc.organizationHospital Universitario Virgen de la Victoria
dc.organizationInstituto de Investigación Biomédica de Málaga-IBIMA
dc.page.number4
dc.provenanceRealizada la curación de contenido 08/08/2024
dc.publisherFrontiers
dc.pubmedtypeCase Reports
dc.relation.projectIDCB06/03/0018
dc.relation.projectIDPI18/01160
dc.relation.publisherversionhttps://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2022.838887/full
dc.rightsAttribution 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectType A insulin resistance syndrome
dc.subjectdiabetes
dc.subjectglucagon-like peptide-1 receptor agonist
dc.subjectinsulin resistance
dc.subjectsodium-glucose cotransporter 2 inhibitor
dc.subject.decsCompuestos de bencidrilo
dc.subject.decsDiabetes mellitus
dc.subject.decsGlucósidos
dc.subject.decsInsulina
dc.subject.decsPéptidos similares al glucagón
dc.subject.decsPéptidos similares al glucagón
dc.subject.decsResistencia a la insulina
dc.subject.meshBenzhydryl compounds
dc.subject.meshDiabetes mellitus
dc.subject.meshGlucagon-Like peptides
dc.subject.meshGlucosides
dc.subject.meshHumans
dc.subject.meshInsulin
dc.subject.meshInsulin resistance
dc.titleCombination Therapy With Semaglutide and Dapagliflozin as an Effective Approach for the Management of Type A Insulin Resistance Syndrome: A Case Report.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number13
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
PMC9046779.pdf
Size:
535.56 KB
Format:
Adobe Portable Document Format
Download

Collections

SAS - Hospital Universitario Virgen de la Victoria
Instituto de Investigación Biomédica de Málaga - Plataforma Bionand (IBIMA)

© 2023 – Repositorio Institucional de Salud de Andalucía - Fundación Pública Andaluza Progreso y Salud - Consejería de Salud y Consumo de la Junta de Andalucía